CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Acute Myeloid Leukemia;   Recurrent Acute Undifferentiated Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Mixed Phenotype Acute Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myelo id Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Mixed Phenotype Acute Leukemia;   Refractory Myelodysplastic Syndrome Interventions:   Drug: Cladribine;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Procedure: Hematopoietic Cell Transplantation;   Drug: Mitoxantrone;   Drug: Mycophenolate Mofetil;   Drug: Mycophenolate Sodium;   Radiation: Total-Body Irra diation Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials